Basis of the antiseizure action of phenytoin

General Pharmacology

Volumn 27, Issue 7, 1996, Pages 1091-1097

  Tunnicliff, G ^a  

^a Indiana University School of Medicine Evansville   (United States)

Author keywords

anticonvulsant; epilepsy; GABA; Na+ channels; phenytoin

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4' CHLORODIAZEPAM; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; DIAZEPAM; ETHOTOIN; FLUMAZENIL; GLUTAMATE RECEPTOR; KAINIC ACID; MEPHENYTOIN; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OUABAIN; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; QUISQUALIC ACID; RADIOLIGAND; SIGMA OPIATE RECEPTOR; SODIUM CHANNEL; UNINDEXED DRUG; VERATRIDINE;

ANTIARRHYTHMIC ACTIVITY; ANTICONVULSANT ACTIVITY; DRUG MECHANISM; EPILEPSY; HEART ARRHYTHMIA; HUMAN; NERVE CELL MEMBRANE; NONHUMAN; PETIT MAL; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEIZURE; SODIUM TRANSPORT;

ANIMALS; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM; EPILEPSY; HUMANS; NEURONS; PHENYTOIN; SODIUM CHANNELS;

EID: 0030273272     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00062-6     Document Type: Review

References (107)

1. Ayala G. F., Lin S. and Johnston D. (1977) The mechanism of action of diphenylhydantoin on invertebrate neurons. I. Effects on basic membrane properties. Brain Res. 121, 245-258.
2. Baskin S. I., Dutta S. and Marks B. H. (1973) The effcts of diphenylhydantoin and potassium on the biological activity of ouabain in the guinea pig heart. Br. J. Pharmacol. 47, 85-96.
3. 3H]norepinephrine efflux. Eur. J. Pharmacol. 254, 307-309.
4. Burnham W. M., Speto L., Okazaki M. M. and Madras B. K. (1981) Saturable binding of [3H]phenytoin to rat brain membrane fraction. Can. J. Physiol. Pharmacol. 59, 402-407.
5. Camerman A. and Camerman N. (1970) Diphenylhydantoin and diazepam: molecular structure similarities and steric basis of anticonvulsant activity. Science 168, 1457-1458.
6. Catterall W. A. (1981) Inhibition of voltage-sensitive sodium channels in neuroblastoma cells by antiarrhythmic drugs. Mol. Pharmacol. 20, 35-362.
7. Catterall W. A. (1992) Cellular and molecular biology of voltage-gated sodium channels. Physiol. Rev. 72 (suppl.), S15-S48.
8. Collingridge G. L. and Lester R. A. J. (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 40, 143-210.
9. Craviso G. and Musacchio J. M. (1983) High-affinity dextromethorphan binding sires in guinea pig brain. II. Competition experiments. Mol. Pharmocol. 23, 629-640.
10. Croucher M. J., Collins J. F. and Meldrum B. S. (1982) Anticonvulsant action of excitatory amino acid antagonists. Science 216, 899-901.
11. Deisz R. A. and Lux H. D. (1977) Diphenylhydantoin prolongs postsynaptic inhibition and ionophoretic GABA action in the crayfish stretch receptor. Neurosci. Lett. 5, 199-203.
12. Delgado-Escueta A. V. and Horan M. P. (1980) Phenytoin: Biochemical membrane studies. Adv. Neurol. 27, 377-398.
13. Deupree J. D. (1976) Evidence that diphenylhydantoin does not affect adenosine triphosphatase from brain. Neuropharmacology 15, 187-195.
14. Esplin D. W. (1957) Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion. J. Pharmacol. exp. Ther. 120, 301-323.
15. Ferrendelli J. A. and Daniels-McQueen S. (1982) Comparative actions of phenytoin and other anticonvulsant drugs on potassium-and veratridine-stlmulated calcium uptake in synaptosomes. J. Pharmacol. Exp. Ther. 220, 29-34.
16. Ferrendelli J. A. and Kinscherf D. A. (1977) Phenytoin: Effects on calcium flux and cyclic nucleotides. Epilepsia 18, 331-348.
17. Fertziger A. P., Liuzzi S. E. and Dunham P. B. (1971) Diphenylhydantoin (Dilantin): Stimulator of potassium influx in lobster axons. Brain Res. 33, 592-596.
18. Festoff B. W. and Appel S. H. (1968) Effect of diphenylhydantoin on synaptosome sodium-potassium ATPase. J. Clin. Invest. 47, 2752-2758.
19. 3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels. Mol. Pharmacol. 42, 1097-1103.
20. Fukuzako H. and Izumi K. (1991) Clinical aspects of the epilepsies. In: GABA Mechanisms in Epilepsy (Edited by Tunnicliff G. and Raess B. U.) pp. 1-30. Wiley-Liss, New York.
21. Gallager D. W., Mallorga P. and Tallman J. F. (1980) Interaction of diphenylhydantoin and benzodiazepines in the CNS. Brain Res. 189, 209-220.
22. Geary W. A., Wooten G. F., Perlin J. B. and Lothman E. W. (1987) In vitro and in vivo distribution and binding of phenytoin to rat brain. J. Pharmacol. Exp. Ther. 241, 704-713.
23. Gilbert J. C. and Wyllie M. G. (1976) Effects of anticonvulsant and convulsant drugs on the ATPase activities of synaptosomes and their components. Br. J. Pharmacol. 5, 49-57.
24. Gilbertson T. A., Scobey R. and Wilson M. (1991) Permeation of calcium ions through non-NMDA glutamate channels in retinal bipolar cells. Science 251, 1613-1615.
25. Gloor P. (1989) Epilepsy: Relationships between electrophysiology and intracellular mechanisms involving second messengers and gene expression. Can. J. Neurol. Sci. 16, 8-21.
26. Goldstein R. E., Penzotti C., Kuehl K. S., Prindle H. K., Hall C. A. and Titus E. O. (1973) Correlation of antiarrhythmic effects of diphenylhydantoin with digoxin-induced changes in myocardial contractility, sodium-potassium adenosine triphosphatase activity, and potassium efflux. Circ. Res. 33, 823-824.
27. Granger P., Biton B., Faure C., Vige X., Depoortere H., Graham D., Langer S. Z., Scatton B. and Avenet P. (1995) Modulation of the γ-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol. Pharmacol. 47, 1189-1196.
28. -10 M). Naunyn-Schmiedeberg's Arch. Pharmacol. 296, 293-296.
29. Hasbani M., Pincus J. H. and Lee S. H. (1974) Diphenylhydantoin and calcium movement in lobster nerves. Arch. Neurol. 31, 250-255.
30. 0 during repetitive electrical stimulation and during pentetrazol induced seizure activity in the sensorimotor cortex of cats. Pflügers Arch. 398, 310-317.
31. Heinemann U., Franceschetti S., Hamon B., Konnerth A. and Yaari Y (1985) Effects of anticonvulsants on spontaneous epileptiform activity which develops in the absence of chemical synaptic transmission in hippocampal slices. Brain Res. 325, 349-352.
32. Ho I. K. and Harris R. A. (1981) Mechanism of action of the barbiturates. Ann. Rev. Pharmacol. Toxicol. 21, 83-111.
33. Hume R. I., Dingledine R. and Heinemann S. F. (1991) Identification of a site in glutamate receptor subunits that controls calcium permeability. Science 253, 1028-1031.
34. 3H](+)-3-PPP label pharmacologically distinct a binding sites in guinea pig brain membranes. Eur. J. Pharmacol. 193, 21-27.
35. Katz J. L., Spealman R. D. and Clark R. D. (1985) Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys. J. Pharmacol. Exp. Ther. 232, 452-461.
36. Kawano H., Sashihara S., Mita T., Ohno K., Kawamura M. and Yoshii K. (1994) Phenytoin, an antiepileptic drug, competitively blocked non-NMDA receptors produced by Xenopus oocytes. Neurosci. Letts. 16, 183-186.
37. +-stimulated ouabain-inhibited ATPase. Proc. Univ. Otago. Med. Sch. 52, 6-7.
38. Krnjevic K. (1991) Significance of GABA in brain function. In: GABA Mechanisms in Epilepsy (Edited by Tunnicliff G. and Raess B. U.) pp. 47-87. Wiley-Liss, New York.
39. Kuo C.-C. and Bean B. P. (1994) Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol. Pharmacol. 46, 716-725.
40. Laffling A. J., Scherr P., McGiven J. G., Patmore L. and Sheridan R. D. (1995) Electrophysiological actions of phenytoin on N-methyl-D-aspartate receptor-mediated responses in rat hippocampus in vitro. Br. J. Pharmacol. 115, 67-72.
41. Lalonde R., and Botez M. I. (1985) Subsensitivity to muscimol-induced catalepsy after long-term administration of phenytoin in rats. Psychopharmacology 86, 77-80.
42. 2- concentration in rat hippocampal slices. Exp. Brain Res. 96, 230-240.
43. Lewin E. and Bleck V. (1971) The effect of diphenylhydantoin administration on sodium-potassium-activated ATPase in cortex. Neurology 21, 417-418.
44. Lipicky R. J., Gilbert D. L. and Stillman I. M. (1972) Diphenylhydantoin inhibition of sodium conductance in the squid giant axon. Proc. Nat. Acad. Sci., USA 69, 1758-1760.
45. Louis S., Kutt H. and McDowell F. (1968) Intravenous diphenylhydantoin in experimental seizures. II. Effect on penicillin-induced seizures in the cat. Arch. Neurol. 18, 472-477.
46. Matthews W. D. and Connor J. D. (1976) Effects of diphenylhydantoin and diazepam on hippocampal evoked responses. Neuropharmacology 15, 181-186.
47. Mayer M. L. and Westbrook G. L. (1987) The physiology of excitatory amino acids in the vertebrate central nervous system. Prog. Neurobiol. 28, 197-276.
48. 3H]SKF-10,047 binding sites (sigma sites) from rat liver membranes. J. Pharmacol. Exp. Ther. 257, 547-554.
49. McLean M. J. and Macdonald R. L. (1983) Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J. Pharmacol. Exp. Ther. 227, 779-789.
50. Meldrum B. S. (1985) Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin. Sci. 68, 113-122.
51. Merritt H. H. and Putnam T. J. (1938) A new series of anticonvulsant drugs tested by experiments on animals. Arch. Neurol. Psychiatry 39, 1003-1015.
52. Morrell F., Bradley W. and Ptashne M. (1958) Effect of diphenylhydantoin on peripheral nerve. Neurology 8, 140-144.
53. 3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. Mol. Pharmacol. 35, 1-5.
54. Musgrave F. S. and Purpura D. P. (1963) Effects of Dilantin on focal epileptogenic activity of cat neocortex. EEG Clin. Neurophysiol. 15, 923-929.
55. Neuman R. S. and Frank G. B. (1977) Effects of diphenylhydantoin and phenobarbital on voltage-clamped myelinated nerve. Can. J. Physiol. Pharmacol. 55, 42-47.
56. 3H-phenytoin binding by diazepam and (+)bicuculline. Life Sci. 33, 409-414.
57. Olsen R.W. (1982) Drug interactions at the GABA receptor-ionophore complex. Ann. Rev. Pharmacol. Toxicol. 22, 245-277.
58. Perry J. G., McKinney L. and De Weer P. (1978) The cellular mode of action of the anti-epileptic drug 5,5-diphenylhydantoin. Nature 272, 271-273.
59. Pincus J. H. (1972) Diphenylhydantoin and ion flux in lobster nerve. Arch. Neurol. 26, 4-10.
60. Pincus J. H., Grove I., Marino B. B. and Glaser G. H. (1970) Studies on the mechansims of action of diphenylhydantoin. Arch. Neurol. 22, 566-577.
61. Pincus J. H. and Hsiao K. (1981a) Calcium uptake mechanisms affected by some convulsant and anticonvulsant drugs. Brain Res. 217, 119-129.
62. Pincus J. H. and Hsiao K. (1981b) Phenytoin inhibits both synaptosomal Ca uptake and efflux. Exp. Neurol. 74, 293-298.
63. Pincus J. H. and Lee S. (1973) Diphenylhydantoin and calcium. Arch. Neurol. 26, 239-244.
64. Popoli P., Pezzola A. and Sagratella S. (1994) Diphenylhydantoin potentiates the EEG and behavioural effects induced by N-methyl-D-aspartate antagonists in rats. Psychopharmacology 113, 471-475.
65. Raabe W. and Ayala G. F. (1976) Diphenylhydantoin increases cortical postsynaptic inhibition. Brain Res. 105, 597-601.
66. Raines A. and Standaert F. G. (1966) Pre-and post-junctional effects of diphenylhydantoin at the soleus neuromuscular junction. J. Pharmacol. Exp. Ther. 153, 361-366.
67. Raines A. and Standaert F. G. (1967) An effect of diphenylhydantoin on post-tetanic hyperpolarization of intramedullary nerve terminals. J. Pharmacol. Exp. Ther. 156, 591-597.
68. Rosenberg P. and Bartels E. (1967) Drug effects on the spontaneous electrcal activity of the squid giant axon. J. Pharmacol. Exp. Ther. 155, 532-544.
69. A but not β-adrenoceptors in the cerebellum of young rats. Eur. J. Pharmacol. 168, 251-255.
70. + channels induced by phenytoin in brains of genetically seizure-susceptible (El) and control (ddY) mice. Neuroscience 62, 803-811.
71. Schafer H. (1985) Chemical constitution and pharmacological effect. Handbk. Exp. Pharmacol. 74, 199-243.
72. Schwartz A., Lindenmayer, G. E. and Allen J. C. (1975) The sodium-potassium adenosine triphosphatase: pharmacological and biochemical aspects. Pharmacol. Rev. 27, 3-134.
73. Schwartz J. R. and Vogel W. (1977) Diphenylhydantoin: excitability reducing action in single myelinated nerve fibers. Eur. J. Pharmacol. 44, 241-249.
74. 3H]-5,5 diphenylhydantoin to rat brain membranes. Neuropharmacology 20, 1115-1119.
75. Sherwin I. (1973) Suppressant effects of diphenylhydantoin on the cortical epileptogenic focus. Neurology, 23, 274-281.
76. Shinozaki H. (1988) Pharmacology of the glutamate receptor. Prog. Neurobiol. 30, 399-435.
77. -+ transport into rat brain synaptosomes by diphenylhydantoin (DPH). J. Pharmacol. Exp. Ther. 185, 272-275.
78. Spain R. C. and Chidsey C. A. (1971) Myocardial Na/K adenosine triphosphatase activity during reversal of oubain toxicity with diphenylhydantoin. J. Pharmacol. Exp. Ther. 179, 594-598.
79. 3H]phenytoin binding in human brain. Can. J. Physiol. Pharmacol. 63, 515-516.
80. Stasheff S. F., Anderson W. W., Clark S. and Wilson W. A. (1989) NMDA antagonists differentiate epileptogenesis from seizure expression in an in vitro model. Science 245, 648-651.
81. 3H]SKF-10,047 to etorphine-inaccessible sites in guinea-pig brain. J. Pharmacol. Exp. Ther. 223, 284-290.
82. Su T.-P., London E. D. and Jaffe J. H. (1988) Steroid binding at σ receptors suggests a link between endocrine, nervous, and immune systems. Science 240, 219-221.
83. Swanson P. D. and Crane P. O. (1972) Diphenylhydantoin and movement of radioactive sodium into electrically stimulated cerebral slices. Biochem. Pharmacol. 21, 2899-2905.
84. Tam S. W. (1983) Naloxone-inaccessible sigma receptor in rat central nervous system. Proc. Natl. Acad. Sci. USA 80, 6703-6707.
85. Toman J. E. P. (1952) Neuropharmacology of peripheral nerve. Pharmacol. Rev. 4, 168-218.
86. Toman J. E. P. (1969) Further observations on diphenylhydantoin. In: Basic Mechanisms of the Epilepsies (Edited by Jasper H. H., Ward A. A. and Pope A.) pp. 682-688. Little, Brown, Boston.
87. Tortella F. C. and Musacchio J. M. (1986) Dextromethorphan and carbetapentane: centrall acting non-opioid antitussive agents with novel anticonvulsant properties. Brain Res. 383, 314-318.
88. Tortella F. C., Witkin J. M. and Musacchio J. M. (1988) Caramiphen, a non-opioid antitussive with potent anticonvulsant activity in rats. Eur. J. Pharmacol. 155, 69-75.
89. Tunnicliff G. and Raess B. U. (1991) GABA neurotransmitter activity in human epileptogenic brain. In: GABA Mechanisms in Epilepsy (Edited by Tunnicliff G. and Raess B. U.) pp. 105-119. Wiley-Liss, New York.
90. Tunnicliff G., Smith J. A. and Ngo T. T. (1979) Competition for diazepam receptor binding by diphenylhydantoin and its enhancement by γ-aminobutyric acid. Biochem. Biophys. Res. Commun. 91, 1018-1024.
91. Tuttle J. B. and Richelson E. (1979) Phenytoin action on the excitable membrane of mouse neuroblastoma. J. Pharmacol. Exp. Ther. 211, 632-637.
92. Wamil A. W. and McLean M. J. (1993) Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons. J. Pharmacol. Exp. Ther. 267, 218-227.
93. Watson E. L. and Woodbury D. M. (1973) The effect of diphenylhydantoin and oubain, alone and in combination, on the electrocardiogram and on cellular electrolytes of guinea pig heart and skeletal muscle. Arch. Int. Pharmacodyn. 20, 389-399.
94. 3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. USA 83, 8784-8788.
95. Weinberger J., Nicklas W. J. and Berl S. (1976) Mechanism of action of anticonvulsants. Role of the differential effects on the active uptake of putative neurotransmitters. Neurology 26, 162-166.
96. Weissman A. D., Casanova M. F., Kleinman J. E., London E. D. and De Souza E. B. (1991) Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol. Psychiatry 29, 41-54.
97. Wilensky A. J. and Lowden J. A. (1972) The inhibitor effect of diphenylhydantoin and microsomal ATPases. Life Sci. 11, 319-327.
98. Willetts J., Balster R. L. and Leander J. D. (1990) The behavioural pharmacology of NMDA receptor antagonists. TIPS 11, 423-428.
99. 3H]batrachotoxinin A 20-α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 22, 627-635.
100. Willow M., Gonoi T. and Catterall W. A. (1985) Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol. Pharmacol. 27, 549-558.
101. Willow M, Kuenzel E. A. and Catterall W. A. (1984) Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25, 228-234.
102. Wong P. T.-H. and Teo W. L. (1986a) Diazepine-sensitive specific binding of phenytoin in rat brain. J. Recept. Res. 6, 297-309.
103. Wong P. T.-H. and Teo W. L. (1986b) The effect of phenytoin on glutamate and GABA transport. Neurochem. Res. 11, 1379-1382.
104. Woodbury D.M. (1980) Phenytom: Proposed mechanisms of anticonvulsant action. Adv. Neurol. 27, 447-471.
105. Worley P. F. and Baraban J. M. (1987) Site of anticonvulsant action on sodium channels: autoradiographic and electrophysiological studies on rat brain. Proc. Nat. Acad. Sci. USA 84, 3051-3055.
106. Yaari Y., Pincus J. H. and Argov Z. (1977) Depression of synaptic transmission by diphenylhydantoin. Ann. Neurol. 1, 334-338.
107. Yaari Y., Selzer M. E. and Pincus J. H. (1986) Phenytoin: Mechanisms of its anticonvulsant action. Ann. Neurol. 20, 171-184.